Adicet Bio Inc (ACET) has disclosed a new risk, in the Innovation / R&D category.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Adicet Bio Inc. faces a significant risk that its clinical trials, including the ongoing Phase 1 study of prula-cel, may fail to demonstrate adequate safety or efficacy, which could block or materially delay regulatory approval and commercialization. Given the inherent uncertainty, high attrition rates, and potential for regulatory authorities to require additional costly and time-consuming studies, adverse outcomes in these trials could materially harm its business prospects and financial condition.
The average ACET stock price target is $28.25, implying 291.82% upside potential.
To learn more about Adicet Bio Inc’s risk factors, click here.